Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report

BMC Cancer

Case Report

Massimo Dall’Olio¹  Claudio Rapezzi¹  Ilaria Gallelli¹  Sara Quercia²  Daniela Rubino²  Claudio Zamagni²  Elena Barbieri²  Marta Cubelli²  Santino Minichillo² 

[1] Cardiovascular Department of the University of Bologna, Via Massarenti, 9, 40138, Bologna, Italy;SSD Oncologia Medica Istituto “F.Addarii”, Sant’Orsola-Malpighi Hospital, University of Bologna, Via Massarenti, 9, 40138, Bologna, Italy;

关键词: Trastuzumab;    Cardiotoxicity;    Monoclonal antibody;    Breast cancer;    Ejection fraction;    Heart failure;   

DOI  :  10.1186/s12885-017-3712-8

 received in 2016-02-10, accepted in 2017-10-30,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundTrastuzumab-related cardiotoxicity has been reported in patients receiving trastuzumab concurrently with other agents, especially with anthracyclines. Cardiac function damage is generally rare, precox and mild with trastuzumab alone.Case presentationWe report the case of a 49 year-old woman affected by metastatic breast cancer who developed trastuzumab-related cardiogenic shock due to pump failure (with LVEF of about 15%) after three months of treatment. After a long hospitalization in the cardiac intensive care unit and a proper treatment, LVEF increased to 50% and, due to a severe progression of disease, trastuzumab was resumed and continued for more than one year.ConclusionThis is a case of particularly severe cardiotoxicity related to trastuzumab treatment, which was recovered with pharmacological treatment and the temporary discontinuation of the treatment. Trastuzumab was safely resumed after clinical and echocardiographic parameters improvement.

【 授权许可】

CC BY   
© The Author(s). 2017